Petadeferitrin
Pharmacosmos is developing petadeferitrin, a small molecule iron chelator, as a potential new treatment for patients with transfusional iron overload.
Pharmacosmos is conducting clinical trials in iron deficiency, iron deficiency anaemia, and oncology care. Our aim is to generate new evidence that may help address treatment challenges and support patients, including those undergoing chemotherapy.
Ferric derisomaltose
In recent years, Pharmacosmos has conducted more than 25 clinical trials across a range of disease areas affected by iron deficiency anaemia, including chronic kidney disease, inflammatory bowel disease, cardiac surgery, and a number of other populations. Among others:
Pharmacosmos is currently conducting a pediatric trial in app. 200 patients with iron deficiency anaemia. For more details, please refer to: ClinicalTrials.gov (ID NCT05179226).
Pharmacosmos is conducting clinical research in iron deficiency and chronic heart failure. For more details, please refer to: ClinicalTrials.gov (ID NCT06929806).
Petadeferitrin
Pharmacosmos is currently conducting a phase II trial in patients with transfusion-dependent thalassemia and iron overload. For more details, please refer to: ClinicalTrials.gov (ID NCT05693909).
Petadeferitrin is investigational and have not been approved for commercial use anywhere in the world. Safety and efficacy have not been established.
Trilaciclib
Pharmacosmos is currently conducting a trial in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving topotecan. For more details, please refer to: ClinicalTrials.gov (ID NCT05874401).
Trilaciclib is currently available in the United States only.
PHARMACOSMOS IS …
A global pioneer in carbohydrate chemistry and a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia.
